---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-281696"
form_type: "8-K"
ticker: "PSNL"
cik: "0001527753"
company_name: "Personalis, Inc."
filed_at: "2024-12-19T23:59:59+00:00"
generated_at: "2026-05-29T01:37:41.712380+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Personalis secures $50M Merck investment, extends Moderna pact, expands Tempus deal

## Summary
- Merck to purchase 14,044,943 shares at $3.56/share for ~$50M; closing expected Dec 19, 2024.
- Merck receives standstill, information, pro-rata participation, and voting rights until 2 years post-close.
- Tempus AI authorized to sell NeXT Personal minimal residual disease test to pharma/biotech clients.
- Moderna extends SOW for V940/mRNA-4157 INT program to up to 10 years; Moderna can license IP for low double-digit millions.
- Personalis to use $10M of proceeds to open ISO-certified lab outside US, mutually agreed with Merck.

## SEC filing metadata
- accession: 0001193125-24-281696
- form_type: 8-K
- ticker: PSNL
- cik: 0001527753
- company_name: Personalis, Inc.
- filed_at: 2024-12-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527753/000119312524281696/0001193125-24-281696-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527753/000119312524281696/d149682d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-281696
- JSON: https://secwatch.observer/filing/0001193125-24-281696.json
- Plain text: https://secwatch.observer/filing/0001193125-24-281696.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.